EUFEST STUDY PDF

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Tojakora Doucage
Country: Tajikistan
Language: English (Spanish)
Genre: Environment
Published (Last): 21 June 2008
Pages: 268
PDF File Size: 15.76 Mb
ePub File Size: 3.66 Mb
ISBN: 989-7-55462-562-9
Downloads: 10622
Price: Free* [*Free Regsitration Required]
Uploader: Dogar

What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year sfudy in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder? Schizophreniform or schizoaffective disorder; 3.

xtudy

Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens. Ethics approval received from the local medical ethics committee. EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: Most studies comparing second generation antipsychotics with classical neuroleptics have been conducted in more or less chronic schizophrenia patients.

At regular time intervals patients are followed-up until 12 months after recruitment: Psychopathology – positive symptoms, negative symptoms, depression, agitation-excitement, disorganisation 2.

Secondary outcome measures At regular time intervals patients are followed-up until 12 months after recruitment: Multicentre, randomised active controlled, parallel group trial. Evid Based Ment Health.

The primary outcome measure was all-cause treatment discontinuation. These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics.

Eligible patients were aged years, and met diagnostic criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder.

Most Related  IVO VUKCEVIC PDF

Result of results found for within. SchizophreniaSchizophreniform disorderSchizoaffective disorder.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Results and Publications Publication and dissemination plan Not provided at time of registration Intention to publish date Participant level data Not provided at time of registration Basic results scientific Publication list 1. Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

The presence of one or more of the contraindications against any of the study drugs. Secondary measures include changes in different dimensions of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions. Loss of retention can be the result of insufficient clinical effect, or lack of tolerability or acceptance. This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year.

This effort represents the first independently designed trans-European schizophrenia treatment trial. Intolerance to one of the drugs in this study 4.

We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia. This outcome is assessed at regular time intervals until 12 months after recruitment. Previous Trial Back to results Next Trial. The principal investigators are Prof. Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3. However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement.

The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

Most Related  BATALLA DE CUITO CUANAVALE PDF

At regular time intervals patients are followed-up until 12 months after recruitment: The study should be finished by the end of and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation eufezt. Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Interventional Secondary study design Randomised controlled trial Trial setting Hospitals Trial type Treatment Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: Effectiveness of antipsychotic drugs sgudy first-episode schizophrenia and schizophreniform disorder: Quality of life 6.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

At present, more than patients have been recruited and randomized in the following countries: The European study of the effectiveness of stufy, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

Intolerance to one of the drugs in this study; 4. Natural history of schizophrenia. Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder 2. The Lancet ; Retention to allocated study drug, which is the time that the patient stays sutdy the randomised drug within the study dose range.

The primary outcome measure is retention in eufet, defined as time to discontinuation of study drug. Amisulpride, Haloperidol, Olanzapine, Quetiapine, Ziprasidone. The presence of one or more of the contra-indications against any of the study drugs. Analysis was by intention to treat.

Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0.